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Introduction
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s 
disease in the United States, is an adult-onset neurodegenerative 
disease affecting primarily motor neurons in the brain and spinal 
cord. The loss of motor neurons leads to the progressive atrophy 
of skeletal muscles and, ultimately, paralysis and death within 
3–5 yr after symptom onset. About 90% of ALS cases are spo-
radic with no known genetic component and 10% are familial. 
Missense mutations in the gene encoding copper/zinc super-
oxide dismutase 1 (SOD1) are associated with 20% of familial 
ALS (Rosen et al., 1993). Transgenic mice overexpressing mu-
tant SOD1 develop a motor neuron disease resembling ALS 
(Gurney et al., 1994). The inbred C57BL/6 SOD1
G37R mice (line 29) 
have a life span of  11–12 mo (late onset), whereas C57BL/6 
SOD1
G93A mice exhibit a life span of  4–5 mo (early onset). 
Although these mice are two well-accepted animal models of 
ALS, the mechanisms leading to neurodegeneration may differ 
among them.
The mechanism by which SOD1 mutants cause motor neuron 
death is still unknown. To date, the most promising hypothesis is 
that the toxicity of mutant SOD1 results from the propensity of 
the misfolded protein mutants to aggregate rather than the ab-
errant copper-mediated catalysis (Johnston et al., 2000; Julien, 
2001). Although SOD1 is traditionally regarded as a cytosolic 
protein, it is noteworthy that both wild-type (WT) and mutant 
SOD1 proteins can be secreted (Turner et al., 2005). A recent study 
proposed the selective secretion of mutant SOD1 mediated by 
chromogranins, which constitutes a potentially toxic pathway that 
can induce infl  ammation and neuronal death (Urushitani et al., 
2006). Mutant SOD1-mediated toxicity is non–cell autonomous. 
The specifi  c expression of mutant SOD1 in neurons, astrocytes, 
or microglia could not provoke motor neuron disease (Gong 
et al., 2000; Pramatarova et al., 2001; Beers et al., 2006). Over the 
years, increasing evidence has indicated the importance of a 
motor neuron milieu and the contribution of nonneuronal cells to 
neurodegeneration in ALS. Clement et al. (2003) demonstrated 
that WT nonneuronal cells delay degeneration and signifi  cantly 
extend survival of mutant-expressing motor neurons. More re-
cently, it was reported that the reduced mutant SOD1 expression 
in microglia contributes to motor neuron protection (Boillee 
et al., 2006) and that WT microglia extend survival of SOD1
G93A 
mice defi  cient in PU.1 (Beers et al., 2006).
Microglia are the main immune cells of the central nervous 
system (CNS). They produce numerous infl  ammatory media-
tors, which are detected in the CNS of both mouse models and 
ALS patients (Nguyen et al., 2002). Up-regulation of toll-like 
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Figure 1.  Exogenous recombinant G93A form of SOD1 protein induces expression of gene encoding proinﬂ  ammatory molecules. (A) Representative 
photomicrographs of in situ hybridization signals showing the mRNA expression of TLR2, MCP-1, and IL-1β in the brain of adult C57BL/6J mice at 2 mo 
of age. Mice received a single intracerebral injection with 1 μl saline, 1 μg/μl of recombinant WT SOD1, or 1 μg/μl G93A mutant SOD1 proteins. 
Mice were killed 24 h after the injection. The coronal sections were taken from x-ray ﬁ  lms. (B) Quantitative analysis of TLR2, MCP-1, and IL-1β mRNA 
expression. Results represent means ± the SEM of three or four mice per group. Asterisk indicates a signiﬁ  cant difference (P < 0.05) from the other groups. 
(C) The same treatments were given to MyD88
−/− mice. Representative in situ hybridization signals in the brain of MyD88
−/− mice. (D) Quantitative 
analysis of mRNA expression in MyD88
−/− mice. (E) Expression of the gene encoding PLP1 (a marker of oligodendrocytes) in the brains of adult 
C57BL/6J that received saline, recombinant WT SOD1, or G93A mutant SOD1 proteins. No sign of demyelination was found. (F) FJB staining was BONE MARROW–DERIVED MICROGLIA IN ALS • KANG AND RIVEST 1221
receptor 2 (TLR2), a reliable index of proinfl  ammatory signal-
ing in microglia/macrophages, also takes place in the spinal 
cord of SOD1
G37R mice (Nguyen et al., 2004). Myeloid differen-
tiation factor 88 (MyD88) is an adaptor protein that plays a criti-
cal role in mediating nuclear factor κB signaling and cytokine 
gene expression (Akira et al., 2006). The innate immune system 
is seriously compromised in MyD88-defi  cient mice (Adachi 
et al., 1998). Macrophages from MyD88 knockout mice did not 
produce interleukin (IL) 6 or TNF-α in response to lipopolysac-
charide (Kawai et al., 2001). Mice defi  cient in MyD88 (MyD88
−/−) 
have impaired IL-1– and IL-18–mediated functions and defects 
in T-cell proliferation (Adachi et al., 1998). We used MyD88
−/− 
mice to study the role of this pathway in the pathogenesis of this 
motor neuron disease.
We show here that extracellular mutant SOD1 induces 
microglial activation in vivo via a MyD88-dependent pathway. 
Our data from chimeric mice suggest a critical neuroprotective 
role of MyD88 in bone marrow–derived microglia (BMDM) in 
SOD1 mutant mice.
Results
Extracellular SOD1 mutant G93A induces 
inﬂ  ammation without being neurotoxic
Adult male C57BL/6J mice at 2 mo of age were given an intra-
cerebral injection of saline, 1 μg of recombinant human SOD1 
WT, or 1 μg SOD1 mutant G93A protein. Mice were killed 3 or 
24 h after the infusion. In situ hybridization was then performed 
across the brains of the mice using the probes for TLR2, mono-
cyte chemoattractant protein 1 (MCP-1), TNF-α, IL-1β, IκBα, and 
IL-12 genes. 3 h after the treatment, the hybridization signals 
were comparable between different treatments (unpublished data). 
However, 1 d after the injection, the signal for TLR2, MCP-1, 
and IL-1β mRNA was higher in the brain of mice that received 
mutant G93A compared with WT SOD1 and saline (Fig. 1, 
A and B). Such an increase in gene expression was signifi  cantly 
prevented in MyD88-defi  cient mice (Fig. 1, C and D). It is inter-
esting to note that the IL-1β mRNA signal remained undetect-
able in the brain of MyD88
−/− mice. The basal levels of TLR2 
are signifi  cantly higher in MyD88
−/− compared with WT mice. 
These data suggest that SOD1 mutant G93A induces proinfl  am-
matory signaling via the MyD88 pathway. WT SOD1 and G93A 
caused a more variable expression pattern of the other immune 
genes measured in the present experiments. They were therefore 
not assessed in the brain of MyD88-defi  cient mice.
We next tested whether such infl  ammatory reaction was 
dependent on the potential neurotoxicity properties of the mutant 
protein. The expression of proteolipid protein 1 (PLP1; a marker 
of altered oligodendrocytes) and fl  uoro-Jade B (FJB; neuro-
degeneration) was not different in the brains of mice admin-
istered either saline, WT SOD1, or mutant SOD1 (Fig. 1, E–G). 
Except for the damage caused by the cannula (Fig. 1, F and G), 
there was no anatomical evidence of demyelination or neuro-
degeneration after intracerebral administration of the mutant 
protein. These data indicate that activation of microglia is not 
a consequence of the neurotoxic effects of mutant SOD1 but a 
direct action of the protein on these immune cells.
Inﬁ  ltration of BMDM by mutant SOD1 and 
SOD1 mice
To determine whether this immune reaction caused infi  ltration 
of BMDM, we generated chimeric mice by transplanting GFP 
bone marrow (BM) cells into irradiated WT mice. 3 mo later, 
these mice received a single intracerebral infusion of either 1 μl 
saline, 1 μg/μl of recombinant human SOD1 WT, or 1 μg/μl 
SOD1 mutant G93A protein. 7 d after the injection, a signifi  -
cantly greater number of GFP cells was found in the brains of 
mice that received G93A protein compared with those challenged 
with SOD1 WT protein or saline (Fig. 2, A and B). Colocalization 
of green autofl  uorescence from GFP BM cells with Iba-1 immuno-
staining (Fig. 2 C, red) provided clear anatomical evidence that 
these GFP cells differentiated into microglia and not other cell 
types (Fig. 2 C). The G93A mutant is therefore able to activate 
microglia and provoke infi  ltration of BMDM.
To determine whether these events also take place in the 
CNS of mouse models of ALS, we generated chimeric mice by 
transplanting BM cells expressing GFP into irradiated SOD1
G37R 
and SOD1
G93A transgenic mice. Mice were killed 3, 6, and 8 mo 
after transplantation (SOD1
G37R; Fig. S1, available at http://www
.jcb.org/cgi/content/full/jcb.200705046/DC1) or at the end stage 
(Fig. 3). A limited number of GFP cells were found in various 
regions of the CNS in both SOD1
G37R and WT groups of mice 
that were killed 3 and 6 mo, respectively, after being transplanted 
with BM cells. Numerous GFP cells were detected in the spinal 
cord and brain stem of SOD1
G37R animals at 8 mo of age (Fig. S1). 
At the end stage, BMDM massively infi  ltrated all affected 
regions of SOD1
G37R and SOD1
G93A chimeric mice (Fig. 3 A). 
All these GFP cells were immunoreactive for Iba-1 in the brain 
and spinal cord of SOD1
G37R and SOD1
G93A chimeric mouse 
models (Fig. 3 B). The data indicate that the infi  ltration process 
begins in the spinal cord and slowly progresses to more rostral 
degenerating regions and that all these cells differentiate into 
microglia in the CNS of mouse models of ALS.
MyD88
−/− BM-derived cells signiﬁ  cantly 
affect the onset and lifespan of 
SOD1
G37R mice
Based on the critical role of the MyD88 pathway in the activa-
tion of microglia by mutant SOD1 and the marked recruitment of 
BMDM in SOD1
G37R and SOD1
G93A chimeric mice, we attempted 
to explore the role of MyD88-competent BMDM. SOD1
G37R and 
SOD1
G93A transgenic mice were irradiated at 2 mo of age and 
transplanted with MyD88
−/− or GFP BM stem cells. C57BL/6J 
WT mice transplanted with MyD88
−/− or GFP BM stem cells 
used as an index of neuronal cell death, which was detected in cells adjacent to the cannula’s tract. Stereological quantitative analysis of the number of 
FJB-positive cells is shown in G. Bar, 100 μm. Results represent mean ± the SEM of four mice per group. No signiﬁ  cant difference was observed between 
the groups.JCB • VOLUME 179 • NUMBER 6 • 2007  1222
were used as controls. We defi  ned disease onset by the age at 
which a 30% decrement in motor performance was measured 
using a rotarod device. There was no signifi  cant difference in 
either symptom onset or lifespan between GFP and SOD1
G93A 
chimera (GFP–SOD1
G93A) and MyD88
−/−–SOD1
G93A groups 
(unpublished data). Both groups of mice became paralyzed 
 1 mo after transplantation. However, SOD1
G37R mice receiv-
ing MyD88
−/− BM cells exhibited a signifi  cantly earlier disease 
onset and shorter lifespan compared with mice receiving GFP 
cells. The disease onset occurred at the mean age of 283 ± 2.76 d 
in MyD88
−/−–SOD1
G37R mice compared with 327 ± 4.13 d in 
GFP–SOD1
G37R mice (Fig. 4 A; P < 0.001). A remarkable dif-
ference was also found in lifespan, with a mean of 297 ± 2.4 d 
for MyD88
−/−–SOD1
G37R mice and 348 ± 3.5 d for GFP–
SOD1
G37R mice (Fig. 4 B; P < 0.001). However, the disease 
duration was not significantly different between these two 
groups (Fig. 4 C; P > 0.05). Consistent with their earlier disease 
onset, MyD88
−/−–SOD1
G37R mice started to lose body weight 
earlier than GFP–SOD1
G37R mice (Fig. 4 D). The mean body 
weight of GFP–SOD1
G37R mice was not as high as nonirradiated 
SOD1
G37R mice, suggesting a potential side effect of irradiation 
and BM transplantation process but not on the lifespan. GFP–WT 
and MyD88
−/−–WT mice did not exhibit any signs of paralysis 
(unpublished data).
Loss of motor neurons and axons in 
MyD88
−/−–SOD1
G37R chimeric mice
To compare the number of motor axons and neurons between 
the different groups, MyD88
−/−–SOD1
G37R chimeric mice were 
killed at the end stage together with MyD88
−/−–WT and GFP– 
SOD1
G37R chimeric mice. All the groups therefore had the same 
age but only MyD88
−/−–SOD1
G37R animals were at the end stage. 
Figure 2.  Inﬁ  ltration of BMDM induced by the 
exogenous recombinant G93A form of SOD1 
protein.  GFP–C57BL/6J chimeric mice re-
ceived a single intracerebral injection with 1 μl 
saline, 1 μg/μl recombinant WT SOD1, or 
1 μg/μl G93A mutant SOD1 proteins. Mice 
were killed 7 d later. (A) GFP-positive cells 
were found in the ipsilateral side of the brain. 
(B) Stereological quantitative analysis of GFP-
positive cells is expressed as volume in cubic 
millimeters and the number of cells. Results rep-
resent mean ± the SEM of four mice per group. 
Asterisk indicates a signiﬁ  cant difference (P < 
0.05) from the other groups. (C) Confocal 
images showing that BMDM (green) are all 
immunopositive for microglial cell marker Iba-1 
(red; Cy3). DAPI was used to stain nuclei (blue). 
Bars: (A) 100 μm; (C) 20 μm.BONE MARROW–DERIVED MICROGLIA IN ALS • KANG AND RIVEST 1223
L5 roots and lumbar spinal cords were taken from these mice and 
processed for the quantifi  cation of motor axons and neurons. 
As depicted by Fig. 5 (A and E), MyD88
−/−–SOD1
G37R had sig-
nifi  cantly fewer motor axons and neurons than MyD88
−/−–WT 
and GFP–SOD1
G37R chimeric mice. MyD88
−/−–SOD1
G37R mice 
had 230 ± 15 axons, whereas 787 ± 36 axons were counted 
in GFP–SOD1
G37R mice (P < 0.05) and 1,001 ± 21 axons in 
MyD88
−/−–WT (P < 0.001). Nissl-stained sections were used 
for the quantifi  cation of motor neurons in the ventral horn of 
lumbar spinal cords. Here again, the number of motor neurons in 
MyD88
−/−–SOD1
G37R mice (6.8 ± 0.1) was signifi  cantly lower 
compared with that of MyD88
−/−–WT (17.4 ± 0.5) and GFP–
SOD1
G37R (14.7 ± 0.9) chimeric mice (Fig. 5, B and F).
It is interesting to note the strong microgliosis in the spinal 
cord of SOD1
G37R, especially in MyD88
−/−–SOD1
G37R chimeric 
mice (Fig. 5, C and D). Both the number of microglial cells and 
Figure 3.  Widespread distribution of BMDM in SOD1 chimeric mice. SOD1
G37R and SOD1
G93A mice were transplanted with BM cells from GFP transgenic 
mice. Spinal cords and brains were taken at the end stage of the animals. (A) GFP-positive cells were detected in the lumbar spinal cord and throughout 
the affected regions of these two types of chimeric mice. (B) Confocal images show that BM-derived GFP-positive cells (green) in the brain and spinal cord 
are all microglial cells (Iba-1, red; Cy3) in both types of chimeric mice. DAPI was used to stain nuclei (blue). Bars: (A) 100 μm; (B) 20 μm. JCB • VOLUME 179 • NUMBER 6 • 2007  1224
the hybridization signal for the gene encoding the innate recep-
tor TLR2 were signifi  cantly higher in mice that were   transplanted 
with MyD88-defi  cient BM cells (Fig. 5, C, D, and G). Transcrip-
tional activation of TLR2 is a reliable marker of the innate 
immune response by microglia (Lafl  amme et al., 2001; Nguyen 
et al., 2002). Whether such a microgliosis contributes or is 
a consequence of the rapid and marked neurodegeneration in 
MyD88
−/−–SOD1
G37R mice remains an open question.
Role of MyD88 in SOD1
G93A and 
SOD1
G37R mice
Because MyD88 plays a critical role in the BMDM of SOD1
G37R 
animals and MyD88
−/−–SOD1
G37R chimeric mice exhibited a 
robust innate immune reaction in the spinal cord (Fig. 5, C 
and D), we created SOD1
G93A and SOD1
G37R mice in the context 
of a MyD88 gene knockout. However, we were not able to 
generate a single SOD1
G93A;MyD88
−/− mouse after >1 yr of 
crossbreeding. It is possible that MyD88 is critical for the 
development and survival of these mice because of the high 
copy number of mutant SOD1 in the SOD1
G93A line, which is 
a rapid and severe mouse model of motor neuron degeneration. 
In contrast, we were able to generate SOD1
G37R;MyD88
−/− 
mice, but no signifi  cant difference was detected in the disease 
onset, duration, or survival between G37R
+/−;MyD88
−/− and 
G37R
+/−;MyD88
+/+ groups (Fig. 6, A–C). However, the body 
weights of G37R
+/−;MyD88
−/− mice were much lower than the 
other groups of mice (Fig. 6 D).
Characteristics of the spinal cord from the 
crossed mice
Crossed mice were killed at 8 mo (presymptomatic stage), 11 mo 
(symptomatic stage), and the end stage. To examine whether 
the context of MyD88 defi  ciency affects motor neurons, Nissl 
staining was performed and motor neurons were counted in 
the ventral horn of lumbar spinal cords. No signifi  cant dif-
ference was found between G37R
+/−;MyD88
+/+ and G37R
+/−;
MyD88
−/− at the presymptomatic stage. Although not statisti-
cally signifi  cant, G37R
+/−;MyD88
−/− mice appeared to have 
fewer motor neurons than G37R
+/−;MyD88
+/+ mice at 11 mo. 
However, G37R
+/−;MyD88
−/− mice had signifi  cantly fewer motor 
neurons in the lumbar spinal cord compared with G37R
+/−;
MyD88
+/+ mice at the end stage of the disease (P < 0.05; 
Fig. 7 A). Immunohistochemistry with the use of microglial cell 
marker anti–rabbit Iba-1 did not reveal any major differences 
in the number of microglia between these two groups at the pre-
symptomatic stage, symptomatic stage, or end stage (Fig. 7 B). 
TLR2 mRNA expression was found to be similar at the presymp-
tomatic and symptomatic stages between G37R
+/−;MyD88
−/− and 
Figure 4.  Earlier disease onset and shorter lifespan of SOD1
G37R chimeric mice transplanted with MyD88
−/− BM cells. (A) The disease onset curve of 
MyD88
−/−–SOD1
G37R chimeric mice (n = 12, male), GFP–SOD1
G37R chimeric mice (n = 11, male), and SOD1
G37R mice (n = 10, male). MyD88
−/−–
SOD1
G37R chimeric mice started the disease phenotype earlier than SOD1
G37R mice that received GFP BM stem cells. (B) Kaplan-Meier survival curve. 
MyD88
−/− BM cells resulted in the earlier death of SOD1
G37R compared with SOD1
G37R mice transplanted with BM cells taken from GFP transgenic mice. 
(C) Disease duration was not signiﬁ  cantly different between the groups. Results represent mean ± SEM of 12 mice in the MyD88
−/−–SOD1
G37R group, 
11 mice in the GFP–SOD1
G37R group, and 10 mice in the SOD1
G37R group. (D) Weekly body weight of MyD88
−/−–SOD1
G37R chimeric, GFP–SOD1
G37R 
chimeric, and SOD1
G37R transgenic mice.BONE MARROW–DERIVED MICROGLIA IN ALS • KANG AND RIVEST 1225
G37R
+/−;MyD88
+/+ groups, but the signal was much higher 
in the lumbar spinal cord of G37R
+/−;MyD88
−/− compared 
with G37R
+/−;MyD88
+/+ at the end stage of the disease (P < 0.05; 
Fig. 7 C).
Discussion
Although ALS was fi  rst described in 1869, the mechanisms in-
volved in the pathogenesis of this neurodegenerative disease still 
remain largely unknown. Several mechanisms that are not mutu-
ally exclusive have been proposed. These include oxidative stress, 
glutamate-induced excitotoxicity, cytoskeletal abnormalities, 
protein aggregation, mitochondrial dysfunction, and, more re-
cently, infl  ammation. The role of infl  ammation and microglia 
in ALS and other CNS diseases is currently a matter of great 
debate and controversy. Although numerous cytokines are up-
regulated in microglia of mice expressing mutant SOD1 transgenes, 
deletion in the gene encoding IL-1β and TNF does not change 
the outcomes of the diseases (Nguyen et al., 2001; Gowing et al., 
2006). However, SOD1
G37R mice that had MyD88-competent 
BMDM developed the disease later, survived longer, and had 
less neurodegeneration than those that were transplanted with 
MyD88-defi  cient BM cells. These data suggest a novel neuro-
protective role of competent BMDM in a mouse model of ALS.
The discovery that  20% of familial ALS cases are caused 
by mutations in SOD1 has enabled the development of animal 
Figure 5.  Motor neuron degeneration and 
microgliosis in MyD88
−/−–SOD1
G37R chimeric 
mice.  MyD88
−/−–SOD1
G37R chimeric mice 
were killed at the end stage together with the 
same age MyD88
−/−–WT and GFP–SOD1
G37R 
chimeric mice. Tissue samples from the three 
groups of mice were analyzed. (A) Images of 
transverse sections of L5 ventral root. Massive 
degeneration was observed in the L5 ventral 
root of MyD88
−/−–SOD1
G37R chimeric mice. 
The counting of motor axons is shown in E. 
(B) Nissl staining of transverse sections of lum-
bar spinal cord. Motor neurons were counted 
and statistical analysis is shown in F. (C) Immuno-
histochemical staining of lumbar spinal cord 
with the use of microglial cell marker anti–rabbit 
Iba-1 followed by incubation with biotinylated 
secondary antibody. The numbers of microglial 
cells were estimated, expressed as number of cells 
per cubic millimeter, and shown in G. (D) In situ 
hybridization using antisense probe for TLR2 
gene. Dark-ﬁ   eld photomicrographs showing 
increased TLR2 mRNA hybridization signals in 
emulsion-dipped lumbar spinal sections from 
MyD88
−/−–SOD1
G37R chimeric mice compared 
with the control mice. (H) Quantitative analysis 
of TLR2 mRNA expression. Results represent 
means ± the SEM of three mice per group. 
Asterisk indicates a signiﬁ  cant difference (P < 
0.05) from the other groups. Number sign indi-
cates a signiﬁ  cant difference (P < 0.05) from 
MyD88
−/−–WT group. Bars, 100 μm. JCB • VOLUME 179 • NUMBER 6 • 2007  1226
and cell culture models and led to much of our current under-
standing of the neurodegenerative mechanisms in ALS. SOD1 is 
a ubiquitously expressed protein, which protects cells from dam-
age by free radicals. ALS often starts focally. It is still unclear 
how the toxicity of mutant SOD1 is propagated from one local-
ized group of cells to another. Based on the recent evidence that 
extracellular mutant SOD1 proteins could be selectively secreted 
and trigger microgliosis and neuronal death in cultured cells 
(Urushitani et al., 2006), we injected WT SOD1 and mutant 
proteins into the mouse CNS. G93A mutant protein was used in 
our experiments because it was the only SOD1 mutant protein 
available to us. In agreement with this study, our data demonstrate 
that mutant SOD1 stimulates infl  ammation and recruitment of 
BMDM. WT SOD1 protein was used as a control to ascertain 
that these effects were specifi  c to the mutant protein and not to 
potential traces of endotoxin. The infl  ammatory response caused 
by G93A is largely dependent on MyD88 signaling but it is still 
not known whether this protein binds to specifi  c immune recep-
tors in microglia. However, G93A is able to stimulate TNF pro-
duction from the microglial cell line (Urushitani et al., 2006) and 
an acute intracerebral infusion of this protein is not neurotoxic. 
We therefore suggest that the infl  ammatory properties of mutant 
SOD1 are directly mediated by the MyD88 pathway in microglia 
and not via other products released by dying cells.
Previous studies have shown that in chimeric SOD1
G93A 
mice, BM-derived cells differentiate into microglia in the spinal 
cord and brain. In addition, it has been suggested that the num-
ber of GFP-positive cells in the spinal cord is associated with 
disease progression (Corti et al., 2004; Solomon et al., 2006). 
In this paper, we generated chimeric SOD1
G37R and SOD1
G93A 
mice and confi  rmed the extensive distribution of GFP-positive 
cells throughout the brain and spinal cord in both mouse models 
of ALS. In accordance with the previous studies, we observed 
few GFP-positive cells in the CNS before the disease onset 
(Fig. S1), but the number of GFP cells greatly increased during 
disease progression (Table S1, available at http://www.jcb.org/
cgi/content/full/jcb.200705046/DC1). More importantly, trans-
plantation of BM from GFP- expressing mice does not affect 
disease progression of either SOD1
G93A or SOD1
G37R mice when 
compared with their respective nonirradiated SOD1 groups. 
In contrast, transplantation of MyD88-defi  cient BM cells dra-
matically changed the disease onset and progression only in mice 
that express human mutant G37R.
The rationale to investigate the role of this adaptor protein 
was based on our initial observation that the MyD88 pathway 
mediates microglial activation and infi  ltration induced by mutant 
SOD1. The results from the chimeric mice suggest that BMDM 
acts as a natural defense mechanism against secreted mutant SOD1. 
Figure 6.  The absence of MyD88 does not affect SOD1
G37R mice. SOD1
G37R mice were bred with MyD88
−/− (G37R
+/−;MyD88
−/−). Four groups of crossed 
mice with the following genotypes were compared: G37R
+/−;MyD88
−/− (n = 9; ﬁ   ve females and four males), G37R
+/−;MyD88
+/+ (n = 9; four 
females and ﬁ  ve males), G37R
−/−;MyD88
−/− (n = 12; ﬁ  ve females and seven males), and G37R
−/−;MyD88
+/+ (n = 12; six females and six males). 
(A) The disease onset curve. (B) Kaplan-Meier survival curve. (C) Disease duration histogram. Results represent mean ± the SEM of nine mice per group. 
(D) Growth curve. No signiﬁ  cant difference was observed in disease onset, survival, or disease duration between G37R
+/−;MyD88
−/− and G37R
+/−;
MyD88
+/+ groups.BONE MARROW–DERIVED MICROGLIA IN ALS • KANG AND RIVEST 1227
MyD88
−/−– SOD1
G37R mice compared with the GFP–SOD1
G37R 
and MyD88
−/−–WT mice at the same age, which explains the 
intriguing earlier disease onset and death of MyD88
−/−– SOD1
G37R 
mice. We also found a more robust innate immune reaction in 
the spinal cord of these mice.
It has been shown that WT nonneuronal cells delayed 
disease onset by a mean of 1.2 mo for SOD1
G37R chimeras and 
extended their survival by 1.1 mo (Clement et al., 2003). A recent 
study demonstrated that substitution of WT microglia for 
SOD1
G93A-expressing microglia prolonged the survival and dis-
ease duration of SOD1
G93A mice but had no effect on the onset 
(Beers et al., 2006). However, reduced levels of mutant SOD1 
in microglia did not change onset and the early disease phase 
but clearly slowed later paralysis (Beers et al., 2006; Boillee 
et al., 2006). These data do not necessarily contradict the exper-
iments using MyD88-defi  cient mice. Indeed, the disease pro-
gression may be infl  uenced by the levels of extracellular mutant 
SOD1 that resident microglia contribute to this extracellular 
pool. This may be an explanation for the neuroprotective prop-
erties of SOD1-defi  cient microglia and such effects may not be 
associated with the immune functions of these cells.
We have previously reported the existence of different 
populations of microglia that may have somewhat opposite 
roles. The double-edged sword of these cells that has been in-
tensively reviewed in the past few years may also depend on the 
origin of microglia in the adult CNS. BMDM are very effi  cient 
in restricting amyloid deposits in a mouse model of Alzheimer’s 
disease, whereas their resident counterparts seem unable to 
phagocyte this toxic protein (Simard et al., 2006). The results 
from this paper support this concept and imply that impairment 
of such natural function of BMDM accelerates the neurodegen-
erative properties of secreted mutant SOD1. It is interesting to 
note that transplantation of MyD88-defi  cient BM cells did not 
change onset or survival of mice expressing human SOD1
G93A. 
These mice reach paralytic endstage  2 mo after BM trans-
plantation. The hematopoietic system takes 7–9 wk to be fully 
restored after lethal irradiation and the percentage of GFP- or 
MyD88-defi  cient cells is low during the fi  rst 4 wk of the chimera. 
This may explain why these cells are unable to modulate the 
disease progression in such an early onset model of neuro-
degeneration. This is not the case in mice expressing SOD1
G37R 
because restoration of BMDM is completed in these animals 
several months before the fi  rst symptomatic signs. The early 
onset may therefore explain why MyD88
−/− BM cells failed to 
change the mean life expectancy of SOD1
G93A.
Because of the potent benefi  cial role of WT BMDM in 
SOD1
G37R mice, the lack of signifi  cant difference in the disease 
onset and lifespan between G37R
+/−;MyD88
−/− and G37R
+/−;
MyD88
+/+ groups of mice may seem surprising. However, his-
tological analysis revealed that microglial cells seem to be 
much more activated in G37R
+/−;MyD88
−/− compared with 
G37R
+/−;MyD88
+/+ mice at the end stage of the disease (Fig. 7 C). 
In addition, at the end stage, G37R
+/−;MyD88
−/− mice lost signi-
fi  cantly more motor neurons than G37R
+/−;MyD88
+/+ mice 
(Fig. 7 A), which suggests that the context of MyD88 defi  ciency 
does affect these SOD1
G37R mice. Neuroprotection is not always 
associated with a signifi  cant extension of survival in mouse 
Figure 7.  Number of motor neurons and microglia in the spinal cord of 
SOD1
G37R mice in a MyD88 knockout context. Crossed mice were killed at 
8 mo (presymptomatic stage), 11 mo (symptomatic stage), and the end 
stage. Results represent mean ± the SEM of four mice per group. (A) Motor 
neurons were counted in the lumbar spinal cord. Note a signiﬁ  cant differ-
ence between the groups of G37R
+/−;MyD88
+/+ and G37R
+/−;MyD88
−/− 
at the end stage (P < 0.05). (B) Immunohistochemical staining of lumbar 
spinal cord with the use of microglial cell marker anti–rabbit Iba-1 followed 
by the incubation with biotinylated secondary antibody. The numbers of 
microglial cells were estimated and expressed as the number of cells per 
cubic millimeter. No signiﬁ  cant difference was found between the groups 
of G37R
+/−;MyD88
+/+ and G37R
+/−;MyD88
−/− at the presymptomatic, 
symptomatic, or end stage (P > 0.05). (C) In situ hybridization was per-
formed using antisense probe for TLR2 gene. Quantitative analysis of TLR2 
mRNA expression showed a signiﬁ   cant difference between the groups 
G37R
+/−;MyD88
+/+ and G37R
+/−;MyD88
−/− at the end-stage (P < 
0.05). These data indicate that microglial cells were more activated in 
G37R
+/−;MyD88
−/− mice.
Indeed, MyD88
−/− BM transplantation led to the earlier disease 
onset and shorter lifespan of SOD1
G37R mice compared with 
mice that received GFP cells. GFP–SOD1
G37R and nonirradiated 
SOD1
G37R mice were used as controls to exclude the possibility 
that these effects were attributable to irradiation. Histological 
analysis revealed a signifi  cant motor neuron and axon loss in JCB • VOLUME 179 • NUMBER 6 • 2007  1228
models of ALS. A recent study has shown that sodium val proate, 
the histone deacetylase inhibitor, exerts neuroprotective effects 
both in vitro and in vivo but it does not improve the survival of 
SOD1
G86R mice (Rouaux, et al., 2007).
It is also important to mention that G37R
+/−;MyD88
−/− 
mice were much smaller than their littermates based on weekly 
body weight. In addition, the numbers of pups per carriage was 
lower in G37R
+/−;MyD88
−/− mice, with a mean of 4.5 com-
pared with 7 pups from SOD1, 6 from MyD88
−/−, and 8 from 
WT mice. Moreover, we were not able to generate a single 
G93A
+/−;MyD88
−/− mouse after >1 yr of crossbreeding be-
tween SOD1
G93A and MyD88-defi  cient mice. We have not been 
able to generate homozygote MyD88
−/− mice in using another 
mouse model of brain disease. Indeed, for >2 yr, we have at-
tempted to breed amyloid precursor protein (APP)/presenelin 1 
transgenic mice with our MyD88
−/− colony and we have ob-
tained only APP;MyD88
+/− but not a single APP;MyD88
−/− 
mouse. This indicates that these MyD88 homozygotes are not 
viable in the presence of highly toxic proteins, such as G93A 
and APP/presenelin 1. Compared with SOD1
G93A, the lower level 
of SOD1
G37R may also explain why we were able to generate 
G37R
+/−;MyD88
−/− mice.
Although unexpected, it is not surprising that the block-
age of the MyD88-dependent intracellular signaling pathway in 
SOD1 mice does not have a marked infl  uence on the survival. 
Indeed, previous studies have shown that exposure of MyD88
−/− 
macrophages with lipopolysaccharide results in the delayed ac-
tivation of nuclear factor κB and MAPKs, which suggests the 
existence of a MyD88-independent signaling pathway (Kawai 
et al., 2001). The paradoxical results from chimeric mice (where 
MyD88-defi  cient BMDM reduced survival) and crossed mice 
(where absence of MyD88 did not affect disease course) are 
best explained by putative compensatory mechanisms activated 
by developmental absence of MyD88. In fact, the strategies are 
very different. G37R
+/−;MyD88
−/− mice may bear the compen-
sation throughout their life, otherwise they will not be viable. 
This is obviously not the case in both models of transgenic 
SOD1 mice transplanted with BM-defi  cient cells because the 
MyD88 gene is present during all the developmental stages and 
is deleted only in BM stem cells at the age of 2 mo.
In summary, our data demonstrate a critical effect of 
MyD88 within BMDM in a mouse model of ALS disease, 
which suggests a novel neuroprotective role of BMDM and sup-
ports the protective functions of microglia at the early stage 
of ALS disease. With further studies, we hope to fi  nd a novel 
approach to optimize the neuroprotective role of BMDM in 
ALS disease.
Materials and methods
Animals
Adult male C57BL/6J mice were purchased from the Jackson Laboratory 
at 2 mo of age. Hemizygous transgenic mice expressing GFP under the 
control of the chicken β-actin promoter and cytomegalovirus enhancer 
were initially also obtained from the Jackson Laboratory. A colony was 
then established and maintained in a C57BL/6J background. Transgenic 
mice carrying G37R (line 29) and those harboring the G93A mutant 
of human SOD1 (B6SJL-TgN[SOD1-G93A]1Gur) were obtained from 
J.P. Julien (Laval University, Québec, Canada). MyD88
−/− mice (in C57BL/6 
background) were provided by S. Akira (Osaka University, Osaka, Japan). 
SOD1
G93A and SOD1
G37R mice were crossed with MyD88
−/− mice to generate 
G93A
+/−;MyD88
−/− and G37R
+/−;MyD88
−/− mice by breeding G93A
+/− 
and G37R
+/− with MyD88
−/− mice, yielding offspring that were hetero-
zygous for the MyD88 gene. The heterozygous offspring were intercrossed 
to obtain breeding pairs of the following genotypes: G37R
+/−;MyD88
−/−, 
G37R
−/−;MyD88
−/−, G37R
+/−;MyD88
+/+, and G37R
−/−;MyD88
+/+. 
With the breeding procedure, we were not able to generate G93A
+/− in 
a context of MyD88 knockout (see Discussion). Animals were acclimated to 
standard laboratory conditions (14-h light and 10-h dark cycle; lights on at 
06:00 and off at 20:00) with free access to rodent feed and water. All animal 
protocols were approved by the Laval University Animal Welfare Committee 
in accordance with the Canadian Council on Animal Care guidelines.
BM transplantation
Irradiation and BM transplantation were performed as described previ-
ously (Simard and Rivest, 2004; Simard et al., 2006). In brief, mice at 
2 mo of age were exposed to 10 gray total-body irradiation using a cobalt-60 
source (Theratron-780; MDS Analytical Technologies). A few hours later, 
the animals were injected via a tail vein with  14 × 10
6 BM cells freshly 
collected and puriﬁ  ed from donor mice. GFP or MyD88
−/− mice at 3–5 mo 
of age were used as cell donors. Irradiated mice transplanted with 
BM cells were housed in autoclaved cages and treated with antibiotics 
(0.2 mg trimethorpine and 1 mg sulfamethoxazole per 1 ml of drinking 
water was given 7 d before and 2 wk after irradiation).
Intracerebral injection
Animals were anesthetized with isoﬂ  urane (Baxter Healthcare Corporation) 
and placed on a stereotaxic apparatus (David Kopf Instruments). The injec-
tion site was reached using a small cannula (28 gauge; Plastic One) at the 
coordinates −2.0 mm lateral and −3.0 mm dorsoventral from the bregma. 
The animals received an infusion of 1 μl of either sterile saline, 1 μg/μl of 
recombinant human WT SOD1, or 1 μg/μl of recombinant G93A mutant 
of human SOD1 protein (provided by M. Urushitani, Shiga University of 
Medical Science, Shiga, Japan) solution over a period of 2 min by a micro-
injection pump (A-99; Razel Scientiﬁ  c Instruments). The animals were killed 
at different time points (3, 24, or 168 h) after the injection.
Tissue collection
Mice were deeply anesthetized via an intraperitoneal injection of a mixture 
of ketamine hydrochloride and xylazine and rapidly perfused transcardi-
ally with 0.9% saline followed by ice-cold borax-buffered 4% PFA, pH 9.5. 
Brains and spinal cords were rapidly removed from the animals, postﬁ  xed 
for 2–3 d, and placed in a solution containing 10% sucrose diluted in 4% 
PFA-borax buffer overnight at 4°C. The frozen tissues were mounted on a 
microtome (Reichert-Jung; Cambridge Instruments Company) and cut into 
25-μm coronal sections. The slices were collected in a cold cryoprotectant 
solution (0.05 M sodium phosphate buffer, pH 7.3, 30% ethylene glycol, 
and 20% glycerol) and stored at −20°C.
In situ hybridization, immunohistochemistry, and immunoﬂ  uorescence
In situ hybridization, immunohistochemistry, and immunoﬂ  uorescence were 
performed as described previously (Laﬂ  amme et al., 1999; Millecamps 
et al., 2006; Simard et al., 2006). 
35S-labeled complementary RNA probes 
for IL-1β, TLR2, MCP-1, TNF-α, IκBα, IL-12, and mouse PLP1 were used for 
in situ hybridization. For immunohistochemistry and immunoﬂ  uorescence, 
rabbit polyclonal anti-ionized calcium binding adaptor molecule 1 (Iba-1, 
1:2,000; Wako Chemicals USA) was used as the primary antibody. 
Microglia that were immunoreactive for Iba-1 were counted in the lumbar 
spinal cord using unbiased stereological techniques. The density of labeled 
cells was estimated by the optical fractionator method using Stereo Investi-
gator software (MBF Bioscience). The lumbar spinal cord was traced with a 
10× Plan Apochromat objective and sampled using a 40× Plan Apochromat 
objective (Nikon). The counting parameters were the distance between 
counting frames (300 μm), the counting frame size (100 × 100 μm), the 
dissector height (13 μm), and the guard zone thickness (1.5 μm).
Morphological and morphometric analysis
Mice were deeply anesthetized, perfused with 0.9% saline, and ﬁ  xed with 
3% glutaraldehyde in PBS buffer, pH 7.4. L5 roots and dorsal root ganglion 
tissue samples were immersed in ﬁ  xative overnight, rinsed in PBS buffer, 
and postﬁ  xed in 1% osmium tetroxide. After three washes with PBS buffer, 
samples were dehydrated in a graded series of ethanol and embedded 
in Epon (Marivac). The thin sections of L5 ventral root were stained with 
toluidine blue and examined under a light microscope. Axons in the L5 ventral 
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FJB staining
FJB method was performed as described previously (Turrin and Rivest, 
2006). In brief, mounted brain sections were dried under a vacuum, dehy-
drated through graded concentrations of alcohol (50, 70, and 100% for 
1 min), rehydrated through graded concentrations of alcohol (100, 70, and 
50% for 1 min), and rinsed for 1 min in distilled water. They were then 
dipped and shaken in 0.06% potassium permanganate for 10 min, rinsed 
for 1 min in distilled water, dipped, and shaken in a solution containing 
0.004% FJB (Histochem), 0.1% acetic acid, and 0.0002% DAPI (Invitro-
gen) for 20 min. The slides were thereafter rinsed three times in distilled 
water for 1 min each, dried, dipped in xylene three times for 2 min each, 
and coverslipped with distrene plasticizer xylene mounting media (Electron 
Microscopy Sciences). The number of FJB-positive cells was counted and 
estimated with Stereo Investigator software.
Nissl staining and motor neuron counting
Mouse lumbar spinal cord was cut into 25-μm-thick transversal sections. 
The sections were washed in distilled water, dehydrated through graded 
concentrations of alcohol (50, 70, 95, and 100%) to xylene, rehydrated 
through graded concentrations of alcohol (100, 95, 70, and 50%), and 
then stained with a 0.25% thionin solution. Thereafter, the sections were 
dehydrated and coverslipped. After the staining, the large motor neurons 
in the ventral horn were counted with Stereo Investigator software. Only 
large multipolar motor neurons with a cross-sectional area ≥250  μm
2 
were considered (Fischer et al., 2004).
Assessment of motor function
The motor function was tested using a rotarod device (10 rpm; Economex 
Controlier; Columbus Instruments) weekly. The amount of time the mice re-
mained on the rotarod was recorded for up to 180 s. The trial was con-
ducted three times for each mouse and the best result of these trials is used 
as the riding time of each mouse.
Confocal laser scanning and regular microscopy
For cell phenotyping, tissue samples were analyzed for colocalization with 
cell type–speciﬁ  c markers using a confocal laser scanning microscope (BX-61) 
equipped with imaging software (Fluoview SV500 4.3; both from Olympus). 
Confocal images were acquired with a 60× Plan Apochromat oil-immersion 
objective (NA 1.35; Olympus) by sequential scanning using a two-frame 
Kalman ﬁ  lter, low speed scans, and a z separation of 0.40 μm. Regular 
2D images were captured on a microscope (C-80; Nikon) ﬁ  tted to a digital 
camera (Retiga EXi Fast; QImaging) and a super-high-pressure mercury 
lamp (Nikon). The images were then processed to enhance contrast and 
sharpness using Photoshop CS2 and ﬁ  gures were assembled using Illustra-
tor CS (both from Adobe).
Quantitative analysis
Quantitative analyses of hybridization signals were performed as de-
scribed previously (Glezer et al., 2003). The intensity of mRNA signals 
were measured on x-ray ﬁ  lm (Biomax Mr; Kodak) under a desktop illumina-
tor (Northern Light; GE Healthcare) using a video system (Charge-coupled 
device video camera module 10.5–15 V; Sony) attached to a 55-mm ex-
tension tube set (Vivitar; Micro-Nikkor) for a Nikon lens and coupled to a 
computer and ImageJ software (1.23p). The OD for each pixel was calcu-
lated using a known standard of intensity and distance measurements from 
a logarithmic specter adapted from BioImage Visage 110s (Millipore).
Statistical analysis
The data were analyzed by one-way analysis of variance followed by 
Bonferroni’s post hoc analysis. P < 0.05 was considered statistically 
signiﬁ  cant.
Online supplemental material
Fig. S1 shows distribution of BMDM in WT and SOD1
G37R chimeric 
mice. Table S1 shows recruitment of BMDM (GFP+/Iba-1+) in the CNS 
of GFP–SOD1
G37R mice at 3, 6, and 8 mo after transplantation. Online 
supplemental material is available at http://www.jcb.org/cgi/content/
full/jcb.200705046/DC1.
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